<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413085</url>
  </required_header>
  <id_info>
    <org_study_id>LMO00-CL-DM-01</org_study_id>
    <nct_id>NCT03413085</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Multifocal Soft Contact Lens in Myopia Control</brief_title>
  <official_title>A Prospective, Randomization, Double-blind Study to Evaluate the Efficacy and Safety of Multifocal Soft Contact Lens in Myopia Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Largan Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Largan Medical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the efficacy and safety of soft lens in myopia
      control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, paired eye comparison, double-blind study aims to evaluate
      the efficacy and safety of &quot;Soft Lens&quot; in myopia control among schoolchildren. A total of 118
      eyes are planned to be enrolled and the expect duration of subject participation will be 48
      weeks not including two weeks of screening period. Data such as refractive error, axial
      length, visual acuity, average wearing hours, self-assessment, adverse events etc. will be
      collected during the study. A total of 10 visits, i.e. a screening visit, a randomization
      visit, and 8 treatment visits are planned. Subjects will be encouraged to complete all
      planned visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Paired-eye comparison</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective cycloplegic refractive error</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in objective cycloplegic refractive error between the two eyes in 48 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Axial length</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in axial length between the two eyes in 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cycloplegic refractive error</measure>
    <time_frame>12, 24, and 36 weeks</time_frame>
    <description>Changes in objective cycloplegic refractive error between the two eyes from baseline after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axial length</measure>
    <time_frame>12, 24, and 36 weeks</time_frame>
    <description>Changes in axial length between the two eyes from baseline after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myopia progression and axial elongation</measure>
    <time_frame>during 48 weeks</time_frame>
    <description>Percent reductions of myopia progression and axial elongation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-assessment by questionnaire 1</measure>
    <time_frame>during 48 weeks</time_frame>
    <description>Analysis of subject self-assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-assessment by questionnaire 2</measure>
    <time_frame>during 48 weeks</time_frame>
    <description>Average wearing hours across the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-assessment by questionnaire 3</measure>
    <time_frame>during 48 weeks</time_frame>
    <description>Reasons and rate for discontinued wear during the study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention name: multifocal soft contact lens/single vision soft contact lens
Left eye: multifocal soft contact lens Right eye: single vision soft contact lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention name: multifocal soft contact lens/single vision soft contact lens
Left eye: single vision soft contact lens Right eye: multifocal soft contact lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>soft contact lens</intervention_name>
    <description>Group A
Group B</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both genders aged between 6 and 15 years

          2. Spherical equivalent refractive error between -1.00D and -10.00D

          3. Visual acuity with contact lens of 20/25 or better in each eye

          4. Astigmatism less than or equal to 1.50D

          5. Anisometropia less than or equal to 1.00D

          6. Agree to wear assigned contact lens and able to comply with the study protocol

          7. Subjects and/or their legal representatives agree to sign informed consent form

        Exclusion Criteria:

          1. Eye disease or vision problem that may contraindicate/interfere with contact lens
             wearing, for example:

               1. Amblyopia

               2. Severe strabismus at investigator's discretion

               3. Pathologically dry eye

               4. Aphakia

               5. Slit lamp findings including but not limited to corneal edema, corneal ulcer,
                  bulbar redness that are more serious than grade 1

               6. Currently ocular infection of any type or inflammation in either eye

               7. Oculomotor nerve palsies

               8. Pupil or lid abnormality in either eye

               9. Severe ocular allergy

              10. Anterior segment infection, inflammation or abnormality

              11. Corneal vascularization greater than 1 mm of penetration

              12. History of herpetic keratitis

          2. Use of bifocals, progressive addition lenses, rigid gas permeable contact lenses,
             orthokeratology lenses, atropine, pirenzepine or any other myopia control treatment
             within 1 month prior to screening visit

          3. Systemic disease that may affect vision or contact lens wearing (e.g. diabetes, Down
             syndrome), autoimmune disease, infectious disease, or immunosuppressive diseases
             recorded in medical charts or informed by caregiver

          4. Surgically altered eyes (e.g. corneal or refractive surgery, not including stye
             removal surgery)

          5. Receiving any medication for long-term use which may interfere with contact lens
             wearing, tear film production, pupil size, accommodation or refractive state, such as
             nasal decongestants (e.g. pseudoephedrine, phenylephrine), antihistamines (e.g.
             chlorpheniramine, diphenhydramine), Prednisolone or Ritalin (methyphenidate)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tzu-Hsun Tsai, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tzu-Hsun Tsai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chao-Wen Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ken-Kuo Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiahn-Shing Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chiun-Ho Hou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei-Yuan Chen, M.S.</last_name>
    <phone>+886-4-36000823</phone>
    <email>weiyuanchen@larganmed.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pei-Hsuan Wu, M.S.</last_name>
    <phone>+886-4-36000823</phone>
    <email>peihsuanwu@larganmed.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tzu-Hsun Tsai M.D.</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tzu-Hsun Tsai, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Tzu-Hsun Tsai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao-Wen Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ken-Kuo Lin M.D.</name>
      <address>
        <city>Taipei</city>
        <zip>105</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken-Kuo Lin, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ken-Kuo Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiahn-Shing Lee M.D.</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiahn-Shing Lee, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jiahn-Shing Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiun-Ho Hou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2018</study_first_submitted>
  <study_first_submitted_qc>January 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myopia control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

